Immunocore Holdings plc (IMCR) SEC Filings & Earnings Calls

Trial results still pending; topline data expected end of 2026; regulatory and commercial risks remain.

“Topline overall survival data expected as early as end of 2026; trial is registrational but results not yet available.”

Dependence on single product KIMMTRAK for revenue; pipeline failure risk.

“All revenue from KIMMTRAK; Phase 3 trials for cutaneous melanoma not yet read out.”

Expected $120M rebate accrual payment in H2 2026 may impact cash flow.

“Company expects to pay approximately $120 million in sales-related rebate accruals in H2 2026.”

Dependence on single product

“KIMMTRAK is our first marketed product; our ability to generate higher levels of revenue from other marketed products, which may never be fully developed or commercialized, depends on the successful development and regulatory approval of one or more of our product candidates.”

Need for additional financing

“We may need additional funding to support our continued operations and pursue our clinical development and growth strategy.” · word for word

Dependence on single product

“KIMMTRAK is our only approved product; revenue entirely dependent on its sales.”

Need for additional funding

“We expect to continue to incur significant operating losses in the foreseeable future and expect our expenses to increase.” · word for word

Clinical development risk

“Our ability to generate higher levels of revenue from other marketed products, which may never be fully developed or commercialized, depends on the successful development and regulatory approval of one or more of our product candidates.” · word for word

Revenue deduction estimation uncertainty

“Our total accrued revenue deductions as of March 31, 2026 were $144.5 million, including amounts of $8.8 million for the critical estimates subject to greater estimation uncertainty.” · word for word

R&D expenses increased due to Phase 3 trial progression, indicating ongoing investment risk.

“R&D expenses for Q1 2026 were $61.1 million, compared to $56.5 million for Q1 2025. This increase was primarily due to clinical expenses related to the progression of our Phase 3 trials.” · word for word

Key executive departures

“Dr. Berman resigned from his position as Executive Vice President, Head of Research & Development effective as of February 27, 2026. ... Ms. St. Leger resigned from the Company, effective May 26, 2026.” · word for word

No stock ownership guidelines for executives

“Discussed but decided not to adopt, as in past years, stock ownership guidelines and performance equity awards given our stage as a public company and the practices of our peers.” · word for word

No performance-based equity awards

“The Committee did not determine over the last three years was the time to introduce Performance Awards.”

Revenue growth expected to moderate in 2026.

“Expect moderating revenue growth in 2026.” · word for word

High R&D spend increasing as pipeline advances.

“R&D expenses increased 24% to $274.9M in FY2025.”

Single product dependence

“Our ability to continue to generate revenues from KIMMTRAK and any other product candidates, if approved, is subject to being considered safe, effective, and having advantages over other therapies.” · word for word

Pricing and reimbursement pressure

“Our revenues from KIMMTRAK may be significantly reduced by both existing and future legislation for drug pricing reforms requiring the payment of rebates.” · word for word

Clinical trial execution risk

“We may be unable to successfully complete additional large-scale, pivotal clinical trials for any product candidates we develop.” · word for word

Competition from TCR-based therapies

“We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of TCR-based therapeutics.” · word for word

Manufacturing and supply chain risk

“If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.” · word for word

Dependence on KIMMTRAK for revenue; moderate growth expected in 2026, indicating potential market saturation or competition.

“Expectations of moderate revenue growth in 2026 for KIMMTRAK.”

Clinical and regulatory risks for pipeline candidates; no specific updates on trial progress.

“Risks include clinical trial outcomes, regulatory approval, and competition.”

Dependence on single product KIMMTRAK for revenue.

“KIMMTRAK is the only commercial product; pipeline still in trials.”

Clinical trial risks for pipeline candidates.

“Phase 3 trials for tebentafusp and brenetafusp; IDMC review but no efficacy data yet.”

Dependence on single product KIMMTRAK

“We have commercially launched KIMMTRAK in 28 countries globally... KIMMTRAK is the lead product from our ImmTAX platform and was the first approved therapy in mUM.” · word for word

Continued operating losses and need for additional financing

“We have incurred significant operating losses and expect to continue to incur significant expenses and operating losses for the near future.” · word for word

Revenue deduction estimation uncertainty

“Our total accrued revenue deductions as of September 30, 2025 were $170.2 million, including amounts of $10.2 million for the critical estimates subject to greater estimation uncertainty.” · word for word